The ongoing professional success of KGI graduates for the past decade shows just how insightful and timely KGI’s creation was for the bioscience world,” President Sheldon M. Schuster, PhD, said of the occasion.

Fittingly, the commencement address was delivered by a leader in the bioscience and pharmaceutical fields: James M. Cornelius, chairman of the board of Bristol-Myers Squibb.

James D. Sterling, PhD, vice president for academic affairs and dean of faculty, recalled joining the still-fledgling KGI in 2000, after being intrigued by its pioneering promise.

“We were at the time seeing the start of a growing movement—that this century would be dominated by the life sciences,” Sterling said. “Though other universities have started similar programs, KGI remains a leader.”

KGI continued the 10th commencement festivities in September by inviting all alumni back to campus for a special celebration. Graduates and their families came to honor KGI’s achievements and catch up on one another’s lives and careers.

Sudhanshu Patwardhan, MD, a member of the first Master of Bioscience (MBS) graduating class in 2002, said that he attended KGI because of its uniqueness.

“It was the right step for me,” he said. “My resume, my CV, couldn’t look any better. The lion’s share of my success is due to KGI.”

Ten commencements later, KGI remains as committed as ever to innovations in the life sciences that can be translated seamlessly from the laboratory to the marketplace. KGI was the first graduate program to combine life science and business into a single curriculum, and it remains at the vanguard of biotechnology education and research.

Tina Song (MBS ’04) agreed that very few programs come close to what KGI offers.

“I thought [KGI] offered a nice combination of what I was looking for—the business and the science,” Song said. “I don’t think I would have been able to get my first job without my KGI education.”

KGI’s pioneering spirit—as well as its tangible results— attracted the first class of 28 students when the program began in 2000, and is what attracted the nearly 100 students who comprise the Class of 2013.

“We are really leading the pack,” Schuster observed. “If you can accuse us of anything, it’s of being really daring in education. That has been said ever since the day we were formed. Building upon KGI’s mission is the most exciting thing I’ve ever done. This is on the leading edge of education.”
’02 Class Success Stories

**JOSH SENO (MBS ’02)**

When he enrolled as one of KGI’s first Master of Bioscience (MBS) students, Josh Seno knew that he wanted to focus his career on biotechnology but was unsure which path to take.

“I didn’t know if I wanted to stay on the science side or move more onto the business side,” said Seno, who had been working as a lab technician after earning his degree in biology from Purdue University.

Fortunately, KGI’s fusion of science and business meant that he could gain the skills and experience he needed to move his career forward, whichever side he ultimately chose.

Of the programs he considered, he said: “KGI was the only one that was a whole new school. It was focused on translating the science into the applications that the industry needs.” So he moved from his native Indianapolis, admitting that KGI’s West Coast location added to its attractions.

After completing his MBS, Seno joined Amylin Pharmaceuticals, where he had interned while at KGI.

“The internship was critical,” he said, noting that KGI made internships a priority from the beginning. His Team Masters Project at Beckman Coulter, Inc. also gave him invaluable exposure to industry, particularly the business and marketing side, he adds.

Seno left Amylin in 2008 after six years and now leads market research and forecasting for Santarus, Inc., a specialty biopharmaceutical company in San Diego.

“For me, the best part of KGI was the relationships,” he said. “We were a close-knit group of 28 students, and the faculty were very accessible and had strong relationships with the industry. I got a good education and industry connections. That’s what propelled me into the field. KGI exceeded my expectations.”

**MARY BADELT (MBS ’02)**

Even as she applied to become one of KGI’s first-ever students, Mary Badelt was confident that the program would meet the needs of industry employers—and she knew it was unique.

“I was looking for something different from the traditional PhD program,” she explained.

KGI also offered career possibilities that she didn’t know existed before she applied.

“It seemed it was either go to medical school or go into a PhD program and become a researcher, and there was nothing in between,” recalled Badelt, who had just completed her undergraduate degree in biological sciences at Mount Saint Mary’s College. “I felt I had absolutely nothing to lose and everything to gain by coming to KGI.”

She described the first year at KGI as full of excitement and enthusiasm from everyone at the institute.

“It was an experiment,” she added, “but I learned a lot. It was all team projects. Coming into industry, that’s all we do—so the group work was very valuable in preparing us for the job market.”

Of her early career after leaving KGI, she said that she was “still exploring.”

“I was definitely interested in either the clinical path or the regulatory path,” she said. “My first job was in the project management, pre-clinical role, and that opened doors for me.” She credits KGI’s preparation with helping open that first door in her career.

Badelt said that it took less than two months to find her first job after she graduated from KGI. For the past eight years, she has been a project manager at Amgen, Inc. currently involved in portfolio management, departmental resource management and cross-functional resource management.

“KGI gave me a good foundation to build upon,” she said.
Keck Graduate Institute is rooted in a great idea. We envision solid education and research driven by collaboration with commercial enterprise that will generate leaders in the life sciences industry. We have spent much time and energy planning, developing and promoting this great idea. However, at the heart of this concept is a need to reach beyond ideas. It is the spirit of action and creation that fuels us to go beyond the laboratory and the classroom to put discovery to work. It’s in our name: Keck Graduate Institute of Applied Life Sciences. It’s in our mission statement: Translating into practice the power and potential of the life sciences. Since we so greatly value turning ideas into reality, we are pleased and proud to report that the idea is working.

More MBS Means More TMPs
After graduating our 10th Master of Bioscience (MBS) class, KGI welcomed the largest student body in our history. One hundred and nine new students entered KGI in the fall, joining more than 50 continuing students; 59 of the new students seek an MBS degree. Our reputation among industry leaders, supported by a history of fruitful partnership, has motivated 18 companies to participate in 2011-2012 as Team Masters Project (TMP) partners. This vote of confidence, exemplified by a willingness to pay the sponsorship fee of $55,000, demonstrates the value that industry places on collaboration with KGI.

New Programs Thrive
The 2010-2011 academic year saw the launch of our Postbaccalaureate Premedical Certificate (PPC) program, with eight students. The program was so successful that fall 2011 enrollment sailed past our growth goals and reached 23 students. In addition, seven of the eight students from last year’s program returned to pursue an MBS degree. Nine newcomers bolstered the ranks of the Postdoctoral Professional Masters (PPM) in Bioscience Management program, further demonstrating the success of our plans in action.

Our Graduates at Work
The strategy is working, and so are our alumni. More than 90% of the 2010 MBS class was employed within six months of graduation. The entire roster of PPM graduates is currently employed. These are glowing endorsements from industry and speak to the high regard for our programs and the training of our alumni, especially in the current difficult job market. Amgen, Inc. alone has hired more than 50 KGI graduates over the past decade.

This past year also saw KGI achieve a number of key successes:

- **TMP Milestone**: Our TMP program surpassed the 100 project mark, with the total currently at 118 projects since the program’s inception in 2001.
- **Accreditation Renewed**: KGI’s overall excellence was affirmed by our reaccreditation from the Western Association of Schools and Colleges.
- **Keck Challenge Recognition**: Although we fulfilled the Keck Matching Challenge Grant in 2009-2010, we officially celebrated this benchmark in spring 2011 with a luncheon honoring the W. M. Keck Foundation for its enduring partnership and ongoing belief in our mission.
- **Donor Wall**: We unveiled our first donor wall to honor the generous benefactors who have helped KGI flourish and who provide a launchpad for further advances and initiatives at KGI.

The New Pharmacist and a New Kind of PharmD
Rapid advances in the field of pharmacy, from automation to genomic medicine, are transforming the pharmacist’s profession into a broader role within the delivery of health care. The industry is hungry for PharmD graduates who understand both the role of community pharmacists and the intricacies of business, regulatory affairs and clinical trials. This is familiar ground to us—reconciling the needs of industry with solid bioscience education. It’s a natural fit that we apply what we’ve learned in refining our MBS program to bridge these areas and create a new model for PharmD education. We are diligently working toward the launch of such a program within the next two to three years.

We hope you will join us in the exciting times ahead for KGI, as we continue to open up fresh pathways in education. No matter what the future holds, KGI will always remain dedicated to our mission of leadership in life sciences education and research that translates into practical results to improve people’s lives.
New Strategic Plan Builds on Founders’ Vision

KGI has begun crafting a new strategic plan, a road map that will guide every major decision at the institute over the next five years. The plan will touch on all aspects of the KGI experience, including curriculum leadership, program growth, enhancement of research and a long-term view of space and facilities needs.

KGI’s first strategic plan was developed in 2004-2005 at a time when the institute offered only one master’s program to a small student body. The school needed to develop a portfolio of offerings to reach more students interested in careers in the applied life sciences. Now, KGI is poised to shape the future of graduate professional life sciences education and applied life sciences research.

“Our mission and our core values have not changed,” said President Sheldon M. Schuster, PhD. “We now have the opportunity to look into the future and ask critical questions about how we lead and continue to innovate at the intersection of business and science.”

KGI held a campus-wide discussion in June 2011 to conduct a Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis to identify key strategic goals. Three core themes emerged, to be further refined during 2011-2012 by appointed committees:

• **Educational Innovation**
  Chaired by Steven Casper, PhD, the Henry E. Riggs Professor of Management, and staff chair Sue Friedman, director of student services, this committee will consider how KGI’s leading academic programs can sustain their competitive edge through interactive and experiential learning opportunities.

• **People and Resources/Culture and Climate**
  Chaired by James D. Sterling, PhD, vice president for academic affairs and dean of faculty, this committee will discuss ways to improve internal resource allocation, faculty and staff retention, process documentation, institutional communication and campus facilities and infrastructure.

• **Research**
  Chaired by Angelika Niemz, PhD, the Arnold and Mabel Beckman Professor and director of research, this committee will review how KGI may best fulfill its translational applied life science research mission through integrating research experiences in the curriculum, expanded PhD offerings, strategic investments in research and entrepreneurship and partnerships with academic institutions, industry and government agencies.

The year-long process for the new strategic plan involves confronting persistent challenges. These include: how KGI will increase its enrollment, expand its financial base and build on existing certificate programs, such as the Postbaccalaureate Premedical Certificate (PPC) program for aspiring medical school students and the Certificate in Bioscience Management for PhD students and postdoctoral fellows.

The new strategic plan will consider the functions of enrollment, corporate relations and research, not only as institutional activities but also as potential sources of revenue, Schuster said.

During fall 2011, KGI will solicit additional feedback from all stakeholders — students, faculty, staff, alumni, industry representatives and trustees — before the KGI Board of Trustees votes on the plan in March 2012.
Annual Fund 2010–2011

We would like to thank all the donors to the 2010-2011 Annual Fund whose generosity helped further KGI’s mission to educate the future leaders of the applied life sciences.

CONTRIBUTORS

Leadership Circle ($50,000-$99,999)
- Astellas USA Foundation
- Beckman Coulter, Inc.
- Robert E. and Winifred B. Curry Foundation
- Anthony and Hallie Caracciolo
- Doris and Marsh Cooper Foundation
- Art and Jane Riggs

Patron’s Circle ($25,000-$49,999)
- Mr. and Mrs. James M. Cornelius
- Dennis and Linda Fenton
- John D. Leland, Jr.
- Bernard Kury
- Jim Weinberg Foundation

Steward’s Circle ($10,000-$24,999)
- Steve and Bonnie Anderson Gift Foundation
- Daniel M. Bradbury
- Gilead Sciences, Inc.
- Judy Hayboer
- John D. Baldeschwieler
- Sheldon M. Schuster, PhD
- Jim Weinberg Foundation

Associate’s Circle ($500-$4,999)
- Aetna Foundation, Inc.
- Amgen Foundation
- AT&T Foundation
- James Sterling and Shenda Baker
- Magalen Bryant
- Kun and Grace Chen (Parent ’07)
- James and Jeannie Cregg
- Donald and Huan DiRocco (Parent ’09)
- Robert and Belte Finnigan
- Ross Grossman
- Kevin Harley
- Samuel and Justine Tsai (Parent ’08)
- Ted and Kyoko Urazaki (Parent ’12)
- Diana L. Walker

KGI Annual Report 2010-2011
Allen Lee (MBS ’09)
James and Frances Lehman
Daniel Lev (MBS ’11)
Lavi and Sarah Lev (Parent ’11)
Darren Leva (MBS ’05)
Gary and Christine Leva (Parent ’05)
Li Liang (MBS ’11)
Pei Jun and Zhang Xie Liang (Parent ’11)
Chao Xian Jessica Lin (MBS ’11)
Helen Liu (MBS ’07)
Melissa Louie (MBS ’05)
James Lu (MBS ’09)
Juan Pablo MacDonald (MBS ’11)
Sir Ramya Madhulathile (MBS ’11)
Jordan Gerton and Brenda Mann
Joshua Manohar (MBS ’11)
Siddhartha Mathur (MBS ’05)
John McNamara (MBS ’07)
Noel Brinkerhoff and Alyson Mead
Silviya Meletath (MBS ’11)
Rachel Melman (MBS ’07)
Isaac Middendorf (MBS ’08) and Naomi Arana (MBS ’08)
Frank and Irma Milling (Parent ’12)
Bandish Momin (MBS ’11)
Shefali Nagrani (MBS ’11)
Ted Nguyen (MBS ’08)
Rizgin Norbu
Nutek Mercantile, Inc.
Tiffany (McAninch) O’Brien (MBS ’02)
Anthony and Linda O’Keefe
Oracle Corporation Matching Gifts Program
Nicholas Osgood (MBS ’05)
Corey Ozar (MBS ’11)
Vikashni Padmakumar (MBS ’10)
Sadhir Pardiwala
Benjamin Pavlik (MBS ’09)
Ryan Peeler (MBS ’07)
Rakesh Penmetsa (MBS ’06)
Nithya Periasamy (MBS ’10)
Michelle Pesce (MBS ’11)
Andrew Peters (MBS ’06)
Pfizer, Inc.
Pioneer Hi-Bred International, Inc.
Marc Pollack (MBS ’11)
Yeshwant Rane (MBS ’11)
James Rankin (MBS ’09)
Animesh and Surnita Ray
William and Mary Roberts
Rockwell Collins Matching Gift Program
Kapil Rohra (MBS ’11)
Delyan Rusev (MBS ’10)
Asavari Joshi-Sachdev and Ravneesh Sachdev (MBS ’06)
Bhiman Sadeghi (MBS ’11) and Fozoozan Farahmand
Christopher (MBS ’04) and Cheryl (Green) Salmen (MBS ’04)
Karen Schneider
Michel Schneider
Briania Schuetz (MBS ’08)
Chance Scott (MBS ’11)
Daniel Segal (MBS ’11)
Garry Seid (MBS ’03)
Trevor Sell (MBS ’11)
Joshua Seno (MBS ’02) and Terri (Poon) Kim (MBS ’02)
Ashish Shah and Payal Kamdar (MBS ’04)
Louis Shamel (MBS ’09)
Anusha Shanker (MBS ’11)
Jungse Shin (MBS ’11)
Ranjith and Neela Silva
Nicoles Sindy (MBS ’09)
Sameer Sivaamunaiapporn (MBS ’11)
Alan and Mary Smith (Parent ’09)
Hans Smith (MBS ’09)
Reid Snowden (MBS ’09)
Bill and Daisy Spurgin (Parent ’08)
Ajitha Srinivasan (MBS ’03)
Nathan Stazewski
Janet Stenno
Thomas Storey (MBS ’03)
Laural Sturr
Bruce Pavlik and Anna Suer (Parent ’09)
Kiirsten Suurkask (MBS ’04)
Sonali Talele (MBS ’10)
Rob Tenerowicz
The San Diego Foundation
Brent Thompson (MBS ’10)
Chandana Thorat (MBS ’11)
Jimmy and Sofia Toro
Sean Tsai (MBS ’08)
Satish Vammi (MBS ’08)
Phyllis Vandeven (Parent ’08)
Raghavan Vasudevan (MBS ’09)
John and Denise Verbrugge (Parent ’10)
Matthew Verbrugge (MBS ’10)
David Vetterlein
Cyrus Virdee (MBS ’09)
Vidya Viswanathan (MBS ’05)
Chivas Wakuta (MBS ’10)
Duane and Puanani Wakuta (Parent ’10)
Wenli Wang (MBS ’02)
Mason and Janet Warner (Parent ’08)
Thomas and Carolisa Weaver (Parent ’12)
Cameron Wellock (MBS ’03) and Sindy Escobar-Alvarez (MBS ’02)
Joseph and Mary Will (Parent ’02)
James and Patricia Wilson (Parent ’09)
Christine Wolf (MBS ’03)
Donald and Karen Wong (Parent ’12)
Yosel Yacop (Parent ’12)
Wah Yan (MBS ’11)
Ranga Yarlagadda (MBS ’10)
Sergey and Rina Zakharov
Mathew Zemel (MBS ’04) and Noreen Ruane
John Zhang (MBS ’11)
Kevin and Kirsti (Scheer) Zitar (MBS ’02)
KGI Plans Expansion with School of BioPharmacy

KGI is planning to launch an ambitious new School of BioPharmacy that will redefine the traditional Doctor of Pharmacy degree (PharmD), preparing pharmacists for a new era of medical practice.

The initiative represents the first school addition under the KGI banner since the institute’s founding in 1997, and it will increase KGI’s standing as a leader and innovator in applied life sciences education.

President Sheldon M. Schuster, PhD, envisioned a new School of BioPharmacy to occupy a distinct market niche. In reaching out to industry representatives, he received overwhelming support.

“KGI’s approach would enhance the professional preparation of pharmacists, making our graduates highly sought-after for employment in the life sciences industry and positioning them to be leaders in modernizing pharmacy practice,” Schuster said.

Planning for the school began in earnest more than a year ago. KGI commissioned a market analysis and convened a 21-member advisory board of leading industry representatives. They were enthusiastic about the concept and its potential.

The health care and bioscience industries are rapidly evolving to adapt to the growth in personalized medicine, advances in genomics and a convergence in the use of therapeutics, diagnostics and medical devices. Traditional PharmD programs have been slow to respond, said James D. Sterling, PhD, vice president for academic affairs and dean of faculty.

“KGI is particularly well-suited to lead in this endeavor because our curriculum and research are already strongly related to pharmaceutical discovery and development,” Sterling said. “We also have an unsurpassed corporate network and career services function to keep our curriculum current and assist our graduates in obtaining employment.”

Nationwide, there is a projected shortage of qualified pharmacists due to an aging population, population growth and increased use of medication per capita. That shortage is expected to increase as millions of now-uninsured and underinsured Americans gain access to health care through national health care reform.

In addition, there are not enough PharmD graduates to develop new drugs and biologics, test them in clinical trials, submit licensing applications, execute business plans and design and manage post-marketing surveillance programs.

Upon completing the four-year PharmD program, KGI graduates will have gained the specialized skills and entrepreneurial edge required to assume leadership positions in the pharmaceutical, biotechnology, medical-device, nonprofit and government sectors.

The curriculum will build on KGI’s existing portfolio of programs, integrating pharmacogenomics, pharmacoconomics, bioinformatics, clinical trial management, risk mitigation and regulatory affairs. As do other KGI students, PharmD students will benefit from KGI’s extensive network of industry partners by participating in internships, establishing professional relationships, and possibly completing a capstone research project.

“KGI School of BioPharmacy graduates will have a wider opportunity range than graduates with a typical Doctor of Pharmacy degree,” said Russell Teagarden, a School of BioPharmacy advisory board member and vice president of clinical practices and therapeutics for Medco Health Solutions. “They will be welcomed by many organizations.”

KGI SCHOOL OF BIOPHARMACY ADVISORY BOARD

David Becker, PhD, chief scientific officer for Pathway Genomics
Daniel Bradbury, B. Pharm, DMS, KGI trustee and CEO of Amylin Pharmaceuticals
Gayle Brazeau, PhD, dean of the University of New England College of Pharmacy
Anthony Caracciolo, B. Pharm, KGI trustee and retired senior vice president of manufacturing and operations for Gilead Sciences
Peter Clagett, vice president of pharmaceutical strategies for WellPoint
Stephen Eck, MD, PhD, vice president of oncology for Astellas Global Pharma Development
Felix Frueh, PhD, president of Medco Research Institute for Medco Health Solutions
Sean Gallagher, PhD, KGI Advisory Council member and vice president and chief technology officer for UVP
Jeffrey Hatfield, PharmD, MBA, president and CEO of Vitate Pharmaceuticals
Jeff Hughes, PhD, former research leader for Roche
Gregg Lapointe, MBA, CEO of Sigma-Tau Pharmaceuticals
John Maguire, PhD, Claremont Graduate University president emeritus
Louis Martinelli, PhD, PharmD, board chair for the Institute for Safe Medication Practices; former dean of Creighton University School of Pharmacy and Health Professions and the University of Pacific Thomas J. Long School of Pharmacy and Health Sciences
Jeff Mason, MD, senior medical director for United Health Care
Alan Rothfeld, MD, KGI adjunct professor; vice president of medical quality for Hollywood Presbyterian Medical Center; chief medical officer for QueensCare Family Clinics and adjunct professor of clinical pharmacology for USC Keck School of Medicine
George Savage, MD, MBA, KGI Advisory Council member and chief medical officer for Proteus Biomedical
Marilyn Standifer Shreve, RPh, president of Tailored Interactive Patient Health
Patrick Sinko, PhD, associate vice president for research at Rutgers University
David Swenson, RPh, vice president of marketing and product management for CareFusion
Russell Teagarden, PhD, BPharm, vice president of clinical practices and therapeutics for Medco Health Solutions and associate dean for research at the Medco School of Pharmacy, Fairleigh Dickinson University
Curtis Tyree, PhD, vice president of operations for HUYA Bioscience International
Four Keck Graduate Institute students spent the 2011 summer in Shanghai as interns under a new ChinaBio® Life Sciences Summer Work-Study Program that could become a model for KGI international internships in the future.

Greg Scott, president and founder of Shanghai-based ChinaBio® LLC, said he was pleased with the students’ level of performance.

“We had them working on a number of things, including internal marketing projects, client projects and a couple of market studies as well,” Scott said. “All of their work was very high caliber.”

Interns Joy Wong, Amrit Sareen and James Hasegawa worked for ChinaBio®, which connects the China life science industry with the rest of the world through consulting, helping raise capital and sponsoring conferences.

“China is now the number two pharmaceutical market in the world and the number two economy in the world,” Scott said. “For any company looking to address major markets globally, China has got to be a major part of their strategy.”

Alex Lee interned for the Roche Group, a multinational pharmaceutical company. Lee said the internship gave him an insider’s view of China’s rapidly growing pharmaceutical industry. He was particularly impressed with his supervisors’ people-management skills.

“It was a whole different working environment,” Lee said. “They really expected me to be independent and take charge of my project, but they were always within reach if I needed any help. They really encouraged me to work harder, and it was something I really enjoyed.” His work focused on exploring recent technology and interesting research that fit into Roche’s corporate strategy.

All four interns lived in the same apartment. They shared many evenings together during the week, but on the weekends they pursued their different interests, whether it was exploring their surroundings, enjoying the night life or shopping.

Instilling a sense of community among the interns was a unique aspect of the ChinaBio® internship, said James D. Sterling, PhD, KGI vice president for academic affairs and dean of faculty. Students had an opportunity to network and discuss their activities on a regular basis. The company also provided transportation and housing and organized events so that the students could connect with one another.

ChinaBio® flew the interns in July to Jinan for the ChinaBio 2011 Investor Forum, where they had an opportunity to review business plan presentations by entrepreneurs.

“The ChinaBio program could be a model for other international institutions and for building relationships between KGI and companies overseas,” Sterling said.

Under the new agreement with KGI, ChinaBio® plans to host a maximum of 15 students for next summer. The program is also open to students from other universities and early career professionals in the life sciences, engineering, business management, economics, international relations, law and public policy fields.

KGI students who participate in the program will receive academic credit for the internships. Others who complete the program will earn the ChinaBio®/KGI China Life Science Business Certificate.
New Leaders Join Board

KGI’s Board of Trustees was delighted to elect three new members in 2010-2011: Rodney Markin, Lilian Wu and Richmond Wolf. These leaders from the fields of medicine, science and business are providing expert knowledge to the board and are helping advance the mission of KGI.

Rodney Markin is the David T. Purtilo Distinguished Professor of Pathology and Microbiology, as well as the courtesy professor of surgery. Previously, he was the senior associate dean for clinical affairs and chairman and president of UNMC Physicians. Board certified in anatomic and clinical pathology, his professional and academic research interests have focused on solid organ transplantation, informatics and clinical laboratory automation, which include robotics, information systems, medical utilization management and outcomes optimization. Dr. Markin founded LAB-InterLink, a technology transfer company of the University of Nebraska Medical Center that provided products for hospital-based laboratory automation systems. He also developed an automated microbiology platform for the U.S. Army Medical Research and Materiel Command. He has 16 patents and more than 300 publications, and he has published nearly 200 abstracts and chapters in books.

Lilian Wu chairs the National Research Council’s Committee on Women in Science, Engineering and Medicine and is a councilor of the Association for Women in Science. She is a member of the S&E Workforce Committee of the Government-University-Industry Research Roundtable of the National Research Council, and a member of the National Science Foundation’s (NSF) Advisory Committee on International Science and Engineering and of NSF’s Corporate Alliance. Wu also was a member of President Clinton’s Committee of Advisors on Science and Technology. She received her PhD in applied mathematics from Cornell University, and her major research interests are analysis of technology-enabled and people-intensive complex systems, particularly in the services sector.

Richmond Wolf has been with Capital World Investors, a division of Capital Research and Management Company, since 2006, when he was an investment analyst in medical technology and a generalist in small- and mid-cap technology companies. Formerly the assistant vice president for technology transfer at the California Institute of Technology, Wolf managed the technology licensing and venture activity at both Caltech and NASA’s Jet Propulsion Laboratory. He received his PhD from Caltech and is a cum laude graduate of Princeton University. Wolf is also a registered patent agent.
Leadership

SENIOR ADMINISTRATION

Sheldon M. Schuster, PhD
President and Professor

James D. Sterling, PhD
Vice President for Academic Affairs and Dean of Faculty, Sidney J. Weinberg Jr. Professor of Applied Life Sciences

Robert W. Caragher
Vice President for Finance and Operations

Karen Schneider
Vice President for Advancement

Elizabeth Wright
Assistant Vice President/Secretary to the Board of Trustees

E. Sofia Toro
Associate Dean of Admissions and Financial Aid

BOARD OF TRUSTEES

Bonnie Anderson
CEO and Co-Founder Veracyte, Inc.

John D. Baldeschwieler, PhD
Professor Emeritus California Institute of Technology

Karen Bernstein
Chairman and Editor in Chief BioCentury Publications

Daniel M. Bradbury, DMS
President and CEO Amylin Pharmaceuticals, Inc.

Catherine M. Burzik
President and CEO Kinetic Concepts, Inc.

Anthony D. Caracciolo
Former Senior Vice President Manufacturing Operations Gilead Sciences, Inc.

Marsh A. Cooper
President M.A. Cooper Consultants, Inc.

Robert E. Curry, PhD
KGI Board Chair Partner Curry Henos Partners Alliance Technology Ventures

Dennis M. Fenton, PhD
Fenton & Associates

Jay Flatley
President and CEO Illuminia, Inc.

Michael A. Friedman, MD
President, CEO & Director of the Comprehensive Cancer Center City of Hope

Judith A. Heyboor
Human Resources Consultant, Former Senior Vice President Human Resources Genentech, Inc.

Peter Barton Hutt, LLB, LLM
Senior Counsel Covington & Burling LLP

Alice T. Kane, JD
Partner Dewey & LeBoeuf LLP

Bernard E. Kurz, JD
Former Vice President and General Counsel Guidant Corporation

Rodney S. Markin, MD, PhD
Associate Vice Chancellor for Business Development Chief Technology Officer University of Nebraska Medical Center

Arthur D. Riggs, PhD
Director Emeritus Beckman Research Institute City of Hope

Sheldon M. Schuster, PhD
President and Professor Keck Graduate Institute

Jack L. Stark
Board Vice Chair President Emeritus Claremont McKenna College

Mark Stevenson
President and COO Life Technologies

Billy Tuszyn
Chairman and Manager Tuszyn Strategic Networks

Murli Tolany
Chairman Emeritus MWH Global, Inc.

Diana L. Walker, JD
Retired Partner O’Melveny & Myers LLP

James F. Wiedergren
Senior Vice President Global Customer Operations Beckman Coulter, Inc.

Richmond Wolf
Vice President and Investment Analyst Capital Group Companies

Lilian Wu
Program Executive Global University Programs IBM Technology Strategy and Innovation

TRUSTEES EMERITI

Alice S. Huang, PhD
Senior Faculty Associate in Biology California Institute of Technology

Howard B. Keck, Jr.
President Brighton Distributing Co.

John D. Leland, Jr.
Consultant and Former Managing Director Dresdner RCM Global Investors

Richard L. McConnell
Former President Pioneer Hi-Bred International, Inc.

Clifford A. Miller
Managing Director Shamrock Holdings

Harlyne J. Norris
Trustee The Kenneth T. and Eileen L. Norris Foundation

Stanford N. Phelps
Chairman S. N. Phelps & Co. and Clear Springs Land Co.

William H. Rastetter
Chairman, Board of Directors Illumina, Inc.

Henry E. Riggs
President Emeritus Keck Graduate Institute

Louis T. Rosso
Chairman Emeritus Beckman Coulter, Inc.

Stephen J. Ryan, MD
President Doheny Eye Institute

Robert E. Tranquada, MD
Emeritus Professor of Medicine and Public Policy University of Southern California

Sidney J. Weinberg Jr.*
Board Chair Emeritus, Senior Director The Goldman Sachs Group, Inc.

*Deceased

KGI Annual Report 2010-2011 11
KGI Unveils First Donor Wall

To create a more permanent and visible means of honoring the generous benefactors who have helped Keck Graduate Institute flourish, KGI has established its first donor recognition wall, located outside the Office of the President.

“This new recognition wall will help underscore the importance of donor support to everything we do at KGI,” said President Sheldon M. Schuster, PhD.

The wall recognizes more than 160 individual, foundation, and corporate donors who have contributed $5,000 or more cumulatively to KGI since the institute’s founding in 1997.

“Our supporters are extremely important to KGI, and we look forward to acknowledging them in a much more public way for their generosity and belief in our mission,” said Karen Schneider, vice president for advancement. “The response we have received to date for this effort has been extremely positive.”

FOLLOWING ARE THE GIVING LEVELS RECOGNIZED ON THE DONOR WALL:

Cornerstone Founder               W. M. Keck Foundation
$1M +                               Founders’ Circle
$500,000 - $999,000                 Chairman’s Circle
$250,000 - $499,999                 President’s Circle
$100,000 - $249,999                 Dean’s Circle
$50,000 - $99,999                   Leadership Circle
$25,000 - $49,999                   Patrons’ Circle
$10,000 - $24,999                   Stewards’ Circle
$5,000 - $9,999                     Ambassadors’ Circle

“Our supporters are extremely important to KGI, and we look forward to acknowledging them in a much more public way for their generosity and belief in our mission.”
Donor Wall Members

CORNERSTONE FOUNDER
W. M. Keck Foundation

FOUNDER’S CIRCLE
Amgen Foundation
Anonymous
The Atlantic Philanthropies
Beckman Coulter, Inc.
Claremont University Consortium
Kelly & Robert Day
Dennis & Linda Fenton
H. Victor Hansen
The Fletcher Jones Foundation
Douglas & Shawn Mackenzie
The Kenneth T. & Eileen L. Norris Foundation
The Ralph M. Parsons Foundation
Stanford & Elizabeth Phelps
Arthur D. Riggs, PhD
The Rose Hills Foundation
Sidney J. Weinberg, Jr.
L. K. Whittier Foundation
WYM Corporation

CHAIRMAN’S CIRCLE
Arnold & Mabel Beckman Foundation
Robert E. & Winifred B. Curry Foundation
Investors Life Insurance Corp.
Joseph J. Jacobs
John D. Leland, Jr.

PRESIDENT’S CIRCLE
The Annenberg Foundation
Anonymous
Beckman Coulter Foundation
Daniel M. Bradbury
Doris & Marshall Cooper Foundation
Garner Glass Company
T. H. Garner
The Hearst Foundations
Hedco Foundation
Hank & Gayle Riggs
The Seaver Institute
Flora L. Thornton Foundation

DEAN’S CIRCLE
American Heart Association
Anonymous
Astellas USA Foundation
John D. Baldeschwieler
Catherine M. Burzik
Michael J. Connell Foundation
Fitzgerald,Abbott & Beardsley LLP
Henry L. Guenther Foundation
Judy Heyboer
Thomas H. Lee
Ronald & Maxine Linde
The George H. Mayr Foundation
Nanostream, Inc.
The Ann Peppers Foundation
PhRMA
Pioneer Hi-Bred International, Inc.
Sheldon M. Schuster, PhD
Simon & Virginia Ramo

The Alfred P. Sloan Foundation
The United Way of Greater Los Angeles
University of Cambridge
Weingart Foundation
Kwang-S. & Ellen Yo

LEADERSHIP CIRCLE
Steve & Bonnie Anderson Gift Foundation
Ernest A. Bates, M.D.
Biogen Idec Foundation
Bristol-Myers Squibb
Bristol-Myers Squibb Foundation
The Capital Group Companies Charitable Foundation
Genentech, Inc.
Genetech Foundation
Gilead Sciences, Inc.
The Haynes Foundation
Bernard Kury
Richard L. McConnell
Clifford A. Miller
The Ohlstrom Foundation, Inc.
Sigma-Tau Pharmaceuticals, Inc.
Jack & Jill Stark
Sun Microsystems, Inc.
Trude C. Taylor
Thermo Electron Corporation
James & Denise Widergren

PATRON’S CIRCLE
American Shared Hospital Services
Amgen, Inc.
Leopold Arnennberg
California Community Foundation
Edward & Nadine Carson
Mr. & Mrs. James M. Cornelius
Joy & Sarah Flatley
David Flores & Karen Bernstein, PhD
Weaver H. Gaines
Independent Colleges of Southern California
Gregory Jenkins
Kenneth Jonsson
James Paul Lower
Al Mann
Rodney S. Markin, MD, PhD
Gerry Ohstrom
Parad
Ian Phillips & Blanca Aguiar
Prairie Ventures LLC
Stephen J. Ryan, MD
Shamrock Holdings of California, Inc.
R. Michael Shamah
The H. Russell Smith Foundation
Michael & Jane Smith
James Sterling & Shenda Baker
St. Jude Medical
Mona & Murli Tolany
Dr. & Mrs. Robert Tranquada
Diana L. Walker

STEWARD’S CIRCLE
Allergan, Inc.
Anonymous

PATRON’S CIRCLE
American Shared Hospital Services
Amgen, Inc.
Leopold Arnennberg
California Community Foundation
Edward & Nadine Carson
Mr. & Mrs. James M. Cornelius
Joy & Sarah Flatley
David Flores & Karen Bernstein, PhD
Weaver H. Gaines
Independent Colleges of Southern California
Gregory Jenkins
Kenneth Jonsson
James Paul Lower
Al Mann
Rodney S. Markin, MD, PhD
Gerry Ohstrom
Parad
Ian Phillips & Blanca Aguiar
Prairie Ventures LLC
Stephen J. Ryan, MD
Shamrock Holdings of California, Inc.
R. Michael Shamah
The H. Russell Smith Foundation
Michael & Jane Smith
James Sterling & Shenda Baker
St. Jude Medical
Mona & Murli Tolany
Dr. & Mrs. Robert Tranquada
Diana L. Walker

STEWARD’S CIRCLE
Allergan, Inc.
Anonymous

AMBASSADOR’S CIRCLE
Christoph Adami & Taylor Kelsey
Aetna Foundation, Inc.
Amylin Pharmaceuticals, Inc.
Herbert & Grace Boyer
Magalen O. Bryant
Bonnie Busenberg & Tom Helliwell
Coopers & Lybrand LLP
Matt & Kathy Croughan
Adam Gross & Rebecca Ebin
Ross & Deborah Grossman
Hughes Electronics
Ionian Technologies, Inc.
Mary Camou Jensen
John E. Kolb
Kenneth Livak
NTD Architects
Pasadena Entretex
David E. L. Foy
Klari Reis
The Rio Honda Foundation
Lou & Maura Russo
Lowell E. Sears
Brandon & Merlene Singleton
Barbara & Barry Zemel

The Baltimore Family Fund
Biogen Idec
Cole-Bellin Education Foundation
Dr. James M. Cregg & Mrs. Jeannie M. Cregg
Greg & Cindy Dewey
Donors Trust, Inc.
Ellis-Leland Family Foundation
Robert & Bette Finnigan
David Galas & Diane Isonaka
John & Christie Glanville
Guidant Foundation
Alice S. Huang, PhD
Alice T. Kane
Lester J. Kaplan
Koret Foundation
The Little River Foundation
Alan Mendelson
Alfred C. Munger Foundation
Charles T. Munger
George T. Ohlstrom, Jr.
Donald O’Neal
Orange County Technology Action Network
Arzu & Jim Osborne
Rathmann Family Foundation
The Rockefeller Foundation
Salesforce.com Foundation
James Schaeffer
Van & B. J. Skilling
Mark Stevenson
Alex Suh
Daniel & Dianne Vapnek
The Sue Ann & John L. Weinberg Foundation
Lillian Wu

AMBASSADOR’S CIRCLE
Christoph Adami & Taylor Kelsey
Aetna Foundation, Inc.
Amylin Pharmaceuticals, Inc.
Herbert & Grace Boyer
Magalen O. Bryant
Bonnie Busenberg & Tom Helliwell
Coopers & Lybrand LLP
Matt & Kathy Croughan
Adam Gross & Rebecca Ebin
Ross & Deborah Grossman
Hughes Electronics
Ionian Technologies, Inc.
Mary Camou Jensen
John E. Kolb
Kenneth Livak
NTD Architects
Pasadena Entretex
David E. L. Foy
Klari Reis
The Rio Honda Foundation
Lou & Maura Russo
Lowell E. Sears
Brandon & Merlene Singleton
Barbara & Barry Zemel

The Baltimore Family Fund
Biogen Idec
Cole-Bellin Education Foundation
Dr. James M. Cregg & Mrs. Jeannie M. Cregg
Greg & Cindy Dewey
Donors Trust, Inc.
Ellis-Leland Family Foundation
Robert & Bette Finnigan
David Galas & Diane Isonaka
John & Christie Glanville
Guidant Foundation
Alice S. Huang, PhD
Alice T. Kane
Lester J. Kaplan
Koret Foundation
The Little River Foundation
Alan Mendelson
Alfred C. Munger Foundation
Charles T. Munger
George T. Ohlstrom, Jr.
Donald O’Neal
Orange County Technology Action Network
Arzu & Jim Osborne
Rathmann Family Foundation
The Rockefeller Foundation
Salesforce.com Foundation
James Schaeffer
Van & B. J. Skilling
Mark Stevenson
Alex Suh
Daniel & Dianne Vapnek
The Sue Ann & John L. Weinberg Foundation
Lillian Wu
Corporate Residency Postdoc Program Successfully Launched

Sanjay Kumar is just the kind of student that KGI had in mind when it established the Corporate Postdoctoral Residency Program. An extension of KGI’s successful Postdoctoral Professional Masters (PPM) in Bioscience Management, the corporate residency version of PPM began in summer 2011 in partnership with Life Technologies, and is designed for researchers such as Kumar, who have a PhD in science or technology and are seeking corporate experience.

Kumar, who earned his doctorate from Roswell Park Cancer Institute and conducted postdoctoral research at Caltech in cellular and molecular biology, jumped at the chance to enroll in the corporate residency PPM after learning about it from KGI trustee Arthur Riggs, PhD.

“It sounded like a dream come true,” said Kumar, whose long-term goals are to keep his scientific abilities honed while working within industry to develop new technologies.

The corporate residency PPM consists of:
- A summer internship in the laboratory of a senior investigator at Life Technologies
- Nine months of schooling at KGI that help PhDs acquire the business and management skills needed to pursue industry-oriented R&D or management careers
- A one-year residency program at Life Technologies upon completion of the PPM degree

KGI established the PPM program because only 30% of doctoral or postdoctoral graduates find faculty jobs, according to Steven Casper, PhD, the Henry E. Riggs Professor of Management and director of the PPM program. Many jobs in the life sciences are found in industry, but students are not taught the ins and outs of corporate life while in school.

“This program fits in well with KGI’s mission to train scientists to successfully gain employment in industry,” said Casper, adding that the corporate experience and networking opportunity afforded through the corporate residency PPM “is unsurpassed for postdoctoral researchers interested in opportunities in the life sciences industry.”

According to Kumar, who has completed the first part of the program and is now pursuing his PPM degree, the only downside he has found so far is that his summer internship at Life Technologies was not long enough.

“It was a wonderful experience,” he said. “The people at Life Tech were so nice and professional that they ensured I fit right in from the first day.”

Kumar acknowledged that his current academic studies at KGI are “intense,” but he is nonetheless enjoying them, saying, “I have already learned so much.”

Nigel Beard, head of global R&D operations in Life Technologies’ Global Science & Innovation Office, said his company was “very excited” to help launch the new program. He added that the company has had a longstanding relationship with KGI and has sponsored numerous Team Masters Projects (TMPs) for the school’s professional students.

“KGI can provide these researchers with advanced scientific training, and Life Technologies can show them what it takes to be an industrial scientist,” Beard said.

Life Technologies is a global biotechnology tools company headquartered in Carlsbad, California. Its customers work across the biological spectrum, from personalized medicine to regenerative science, molecular diagnostics, agricultural and environmental research and 21st century forensics.
TMP Program Honors Returning Corporate Sponsors

Corporate sponsors of the Team Masters Project (TMP) program now have the opportunity to increase their visibility on the Keck Graduate Institute campus through a new recognition program that rewards their continuing support. Companies that commit to consecutive years of sponsorship can customize a TMP meeting room with their corporate identity.

“This new recognition program is just another way to show KGI’s appreciation for our TMP sponsors, especially those who return year after year to support our students,” said Diana Bartlett, assistant vice president and director of corporate partnerships. “The company’s logo appears on its TMP room, strengthening the bond between sponsor and team. It also will present a continuous reminder to KGI faculty, staff, students and visitors about the company, its values and reputation.”

The TMP program has grown dramatically in both sophistication and size since it was established in 2001. The number of TMPs each year has more than doubled over the past decade, with six or seven in the early years to 18 teams today.

What hasn’t changed is the competitive advantage TMP provides to both students and sponsoring companies.

“The programs at KGI are ideal for developing scientists who have an understanding of business. Through the TMP, we have access to a group of bright young creative students who can take a fresh look at a project,” said James F. Widergren, a KGI trustee and senior vice president of global customer operations at Beckman Coulter, Inc., which has sponsored nine TMPs through the years.

Another benefit is the TMP’s value as a recruiting tool. “We have the chance to meet, work with and evaluate students,” he added. “And there’s an altruistic side. We feel it’s important to give back to the community and the educational system—particularly to strengthen the life sciences industry, whether these students go on to work for us or someone else.”

KGI differs from most other institutions with experiential capstone programs in that a TMP is required rather than optional. At a full academic year, it also has a longer duration—many of the others are only a semester long—and it is fully integrated into the curriculum.

“At KGI, one day a week is set aside for TMP, ensuring sufficient time is available to devote to the project,” Bartlett said.

“The fact that these companies come to KGI and seek support from our students and faculty when they could go to a consulting company instead is really impressive,” Khushnuma Bhesania said. “The problem you’re solving for them is a real one. The company is banking on you for that data and those results. It makes it very worthwhile.”

KGI students meet in their TMP room featuring the logo of the team’s corporate sponsor
The KGI Advisory Council provides industry insight, marketplace feedback, and support for KGI’s corporate outreach. The council includes leaders from biotech, pharmaceutical, medical device, service, and bio companies.
James Schaeffer  
Executive Director of Licensing & External Research-West Coast, Merck

Randy Schatzman  
Co-Founder, President and Chief Executive Officer, Alder Pharmaceuticals, Inc.

Steve Shire  
Staff Scientist and Group Leader in the Late Stage Pharmaceutical and Device Development Department, Genentech

Harmeet Sidhu  
Chief Scientific Officer, OxThera

Alex Suh  
Managing Director, California Technology Ventures LLC

Brian Sullivan  
Product Development Team Leader, IIX Agentase

James D. Talton  
Co-founder, President and CEO, Nanotherapeutics

J. Russell Teagarden  
Vice President, Clinical Practices & Therapeutics, Medco Health Solutions, Inc.

Robert Tenerowicz  
Vice President of Operations, XOMA

J. Russell Teagarden  
Vice President, Clinical Practices & Therapeutics, Medco Health Solutions, Inc.

Gino van Heeke  
Executive Director, Novartis Institutes for BioMedical Research

J. Russell Teagarden  
Vice President, Clinical Practices & Therapeutics, Medco Health Solutions, Inc.

Shu Chien  
Professor and Director, Whitaker Institute of Biomedical Engineering, University of California at San Diego

T. (Teo) Forcht Dagi, MD  
Partner, HLM Venture Partners

Larry Gold  
Founder, Chief Executive Officer and Chairman of the Board, Somalogic

BJ Hull  
Site Director (retired), Gilead Sciences, Inc.

Robert L. Jones  
Vice President, Human Resources, CancerVax

Vaughn M. Kailian  
Vice Chairperson, Head of Commercial Operations and Therapeutic Franchises (retired), Millennium Pharmaceuticals

Gail Maderis  
President, Bay Bio

Alfred E. Mann  
Chairman and Chief Executive Officer, Advanced Bionics

Michael A. Mussallem  
Chairman and Chief Executive Officer, Edwards Lifesciences

Stephen D. O’Connor  
Chief Executive Officer, Nanostream

Joseph D. Panetta  
President and Chief Executive Officer, BIOCOM

John B. Rogers  
President and Chief Executive Officer, EcoArray

David Sadava  
Pritzker Family Foundation Professor of Biology, Joint Science Department, The Claremont Colleges

Thomas P. Stagnaro  
President and Chief Executive Officer, Americas Biotech Distributor

Daniel Vapnek  
Founding Senior Vice President of Research (Retired), Amgen

J. Craig Venter  
President, The Center for the Advancement of Genomics

Bradley Wigglesworth  
Site Manager (retired), Gilead

Rick Winningham  
CEO, Theravance

MBS student Laura Wilson explains her summer internship poster to Advisory Council member David Rozzell
Keck Graduate Institute unveiled its new Science Heritage Center in 2010-2011, featuring inventions that revolutionized the bioscience and diagnostic industries.

The collection, on loan from Beckman Coulter, Inc., showcases inventors Arnold Beckman and Wallace Coulter, who were pioneers in the development of analytical instruments.

“We probably have the best display of Beckman Coulter historical instruments in the world,” said James Osborne, PhD, the Robert E. Finnigan professor and director of the Center for Biomarker Research, who was instrumental in bringing the display to KGI.

Beckman Coulter officials had an opportunity to view the Science Heritage Center during a dinner in June that KGI hosted for retired Beckman Coulter vice presidents. Osborne, who previously worked for Beckman Coulter, said the dinner was like a mini-reunion.

“They loved the display,” Osborne said. “This is part of their careers; they helped develop, market and commercialize a lot of these instruments during their tenure at Beckman Coulter Inc. These items are very personal to these retired executives.”

Beckman Coulter has been a strong supporter of KGI and its students, according to Osborne. The company has funded eight Team Masters Projects and donated laboratory equipment over the years.

In addition to the equipment, Beckman Coulter provided the cabinets for the Science Heritage Center, along with a series of colorful scientific posters to complement the exhibit by illustrating bioscience breakthroughs that facilitated advances in the detection and prevention of disease.

“Students actually get to follow the career of someone in the life sciences industry who essentially changed the landscape many times by changing the way analyses were performed as well as automating the process,” Osborne said. “It puts a touch of realism into the coursework we have here at KGI.”

The exhibit, arranged in chronological order, begins with the pH Meter invented by Beckman in 1935 to determine the acidity of lemon juice. The Beckman pH meter, which sparked a chemical revolution, was designated a National Historical Chemical Landmark by the American Chemical Society in 2004.

Among the many instruments in the exhibit are:

- The DU Spectrophotometer, which revolutionized laboratory testing by reducing the time needed to determine the chemical makeup of solutions and substances from weeks to minutes.
- The DNA Sequencer, which is the primary technology used to sequence the human genome.
- The First Automated Blood Cell Counter, which increased the speed, convenience and accuracy of counting blood cells over the prevailing method of using a microscope and hand counter. Today, more than 95% of all blood cell counters are based on the Coulter Principle.

Eventually, Osborne wants to add interactive video and audio to the exhibit to help viewers better understand the importance and impact of the various displays. He would like to see high school students and college undergraduates tour the exhibit in hopes of sparking their interest in translating advances in life science into innovative commercial products. Meanwhile, he is encouraging other companies to showcase their inventions as well in the Science Heritage Center.

“Students actually get to follow the career of someone in the life sciences industry who essentially changed the landscape many times by changing the way analyses were performed as well as automating the process,” Osborne said. “It puts a touch of realism into the coursework we have here at KGI.”
Faculty members come to KGI from well-established academic positions and successful biotechnology companies. They combine impressive university credentials with a keen awareness of the industry’s latest developments to bring new ideas and innovations into their classrooms and labs.

Christoph Adami, PhD  
Professor: Computational and Evolutionary Biology, Bioinformatics, Artificial Life, Neural Systems

Craig Adams, PhD  
Research Associate Professor; Director, Team Masters Project; Assistant Director, Center for Biomarker Research

Luann Bangsund, PhD  
Professor of Practice; Director, Master of Bioscience Program: Firm Valuation, Private Equity, New Venture Finance

Gail D. Baura, PhD  
Professor: Bioengineering, Machine Learning, Medical Devices, Engineering Ethics

Daniel T. Byrd, PhD  
Assistant Professor: Strategic Management, Social Network Analysis and Diffusion of Innovations

Steven Casper, PhD  
Henry E. Riggs Professor of Management: Marketing Assessment, Biotechnology Clusters, Corporate Governance

James M. Cregg, PhD  
Research Professor: Recombinant Proteins, Pichia pastoris, Gene Expression, Peroxisome Biogenesis

Matthew S. Croughan, PhD  
George B. and Joy Rathmann Professor; Director, Amgen Bioprocessing Center: Bioprocessing, Pharmaceutical Manufacturing

David J. Galas, PhD  
Research Professor: Nucleic Acid Analysis Technologies, Genetics and Functional Genomics, Biological Networks

Nancy Lam, PhD  
Assistant Professor: Management and Organizational Behavior

Angelika B. Niemz, PhD  
Arnold and Mabel Beckman Professor, Director of Research: Medical Diagnostics, Self-assembly and Molecular Recognition in Biological and Man-made Systems

James C. Osborne, PhD  
Robert E. Finnigan Professor of Applied Life Sciences; Director, Center for Biomarker Research: Protein Biophysical Chemistry, Protein Structure and Function, Diagnostic Applications, Lab Automation

M. Ian Phillips, PhD  
Norris Professor of Applied Life Sciences; Director, Center for Rare Disease  
Therapies: Biology of Stem Cells, Gene Regulatory Networks, Rare Diseases

Animesh Ray, PhD  
Professor; Director, PhD Program and Center for Network Studies: Gene Function, Gene Regulatory Networks, DNA Repair, Gene Targeting, DNA Computing, Systems Biology

Molly B. Schmid, PhD  
Professor and Entrepreneur-in-Residence: Antimicrobial Drug Discovery, Antibiotics, High Throughput Screening, Microbial Genomics, Animal Models of Infection

Steve Sommer, MD, PhD  
Research Professor: Mutation Expert-based Diagnosis and Personalized Medicine, Genetic Predisposition to Neuropsychiatric Illnesses, and Spontaneous Mutagenesis and its Relation to Cancer and Other Diseases

Sheldon M. Schuster, PhD  
President and Professor: Mechanisms of Enzyme Action, DNA-Protein Biosensors, Role of Mycoplasma in Cancer

James D. Sterling, PhD  
Sidney J. Weinberg, Jr. Professor of Applied Life Sciences, VP for Academic Affairs and Dean Faculty: Microfluidics, Microfabrication, Laboratory Automation, Biochips, Biosensors, Biotransport, Systems Modeling, Flow Cytometry

ADJUNCT AND VISITING FACULTY

Phil Barnett, PhD  
California Institute of Technology  
Jet Propulsion Laboratory (Retired)

Diana Bartlett  
Director  
Corporate Partnerships, KGI

Randy Berholtz, JD  
Attorney in Private Practice

Ashish Bhan  
Instructor

Tathagata Dasgupta, PhD  
Partner and EVP  
Xavor Corporation

Larry Grill, PhD  
Professor  
Pitzer College

Gerard Jensen, PhD  
Director of Development and Technical Services, Gilead Sciences

Rick Johnston, PhD  
Director, Center for Biopharmaceutical Operations  
University of California, Berkeley

Brian Keeley, PhD  
Professor of Philosophy  
Pitzer College

David Margolese, PhD  
Venture Advisor

John Milton, MD, PhD  
Professor of Biology  
William R. Kenan Jr. Professor of Computational Neuroscience  
Joint Science Department, The Claremont Colleges

Eric Morfin  
Founder  
BioPharmaPM

Alan F. Rothfield, MD  
Keck School of Medicine  
University of Southern California

David E. Sadava, PhD  
Pritzker Family Foundation Professor of Biology, Joint Science Department, The Claremont Colleges, Emeritus

David Slade, PhD  
Visiting Assistant Professor of Chemistry  
Joint Science Department  
W. M. Keck Science Center

David Vetterlein, PhD  
Principal Consultant  
Alliance BioProcess Consulting

Steven Youro, PhD  
Writing Program, Humanities Division  
California Institute of Technology

PROFESSORS-AT-LARGE

Michael S. Waterman, PhD  
Professor of Biological Sciences, Mathematics, Computer Science  
University of Southern California

Susan R. Wessler, PhD  
Distinguished Professor of Genetics  
UC Riverside
Profiting from the Nonprofit Experience

Each summer several Keck Graduate Institute students benefit from a unique opportunity for paid internships with government and nonprofit agencies, thanks to a grant from the Fletcher Jones Foundation. With placement in such organizations as the Food & Drug Administration (FDA), the National Organization for Rare Disorders (NORD) and City of Hope, KGI’s Fletcher Jones Scholars gain field experience while exploring potential career options.

“The internship provided me with invaluable experience seeing the pharmaceutical industry from the patient’s perspective,” said Joe Head, a Master of Bioscience (MBS) student who served at NORD as a medical writer and life sciences intern. “NORD effectively bridges the gap between patients, support organizations and drug manufacturers to alleviate the unnecessary burdens placed on already struggling individuals. The internship made it clear to me that there is more to decisions than just the bottom line.”

In addition to the professional experience, the students also valued the opportunity to have a meaningful impact on society.

“For MBS student Pratyusha Ghoshal, who spent his summer at City of Hope, the internship gave him an opportunity to observe—and actively support—a vibrant technology transfer team.

“PRATYUSHA GHOSHAL

JOE HEAD

I helped the department write 17 market disclosures and helped them identify and market some of their technologies to industry,” he said. “This experience helped me understand the workings of a technology transfer office with regard to valuation and marketing of technologies, which ties in to my ambition of being in business development.”

“KGI and the Fletcher Jones Foundation have provided students with a great platform to create a difference in the lives of others through our work with nonprofits,” said Abhishek Chandiramani, an MBS student who interned at City of Hope as a licensing and marketing assistant in the Technology Licensing office. Among his projects, he helped two scientists develop a business case for a breakthrough project that identifies and addresses the psychosocial needs of cancer patients.

Fletcher Jones Scholars also can testify that their internships yield value long after they end.

Sonali Talele (MBS ’10), who interned with the FDA Office of Orphan Products Development (OOPD) in 2009, said the experience “helped create a foundation on which I based my future career goals to work in the clinical/regulatory field.” At OOPD Talele assisted on a project that involved tracing and analyzing the trends of approvals for rare disease treatments over time.

The Fletcher Jones Foundation established the Fletcher Jones Foundation Endowed Scholarship Fund at KGI in 2007 with a $125,000 grant, with a follow-on grant of $500,000 in 2010.

Established in 1969 by Fletcher Jones, co-founder of Computer Sciences Corporation, a global business technology firm, the foundation is governed by an independent board of trustees, and its primary mission is the support of private colleges and universities in California.
Corporations and Foundations

Corporations and foundations annually support KGI with gifts for special programs or investments in the future to establish a permanent endowment. The following supporters contributed to KGI during FY 2010-2011.

Aetna Foundation, Inc.
Amgen Foundation
Ann Peppers Foundation
Astellas USA Foundation
AT&T Foundation
Baltimore Family Fund
Beckman Coulter Foundation
Beckman Coulter, Inc.
Cole-Belin Education Foundation
Cornelius Family Foundation
Donors Trust Inc.
Fidelity Investments Charitable Gift Fund
Fletcher Jones Foundation
Genentech Foundation
Gilead Sciences, Inc.
Investors Life Insurance Corporation
John and Sandra Leland Foundation
John Baldeschwieler & Marlene Konnar Foundation
Kenneth T. and Eileen L. Norris Foundation
Nutek Mercantile, Inc.
Oracle Corporation Matching Gifts Program
Pfizer Inc.
Pioneer Hi-Bred International, Inc.
Ralph M. Parsons Foundation
Rockefeller Foundation
Rockwell Collins Matching Gift Program
Rose Hills Foundation
San Diego Foundation
Sidney J. Weinberg, Jr. Foundation
Steve and Bonnie Anderson Gift Foundation
US Charitable Gift Fund
W. M. Keck Foundation

LINDA AND DENNIS FENTON
MARSH A. COOPER
Fellowships and Professorships

The following contributors made gifts to establish endowments, significant fellowships, or special programs that benefited KGI in 2010-2011.

- **Ann Peppers Foundation**
  - Ann Peppers Foundation
  - Endowed Fellowship Fund

- **Daniel Bradbury**
  - Bradbury Endowed Fellowship Fund

- **Bristol-Myers Squibb Foundation**
  - Bristol-Myers Squibb Foundations
  - Founders Circle Fellowship

- **Catherine Burzik**
  - Catherine and Francis Burzik
  - Founders Circle Fellowship

- **Tony Caracciolo**
  - Anthony and Hallie Caracciolo
  - Founders Circle Fellowship

- **Marsh A. Cooper**
  - Marsh A. Cooper Founders Circle Fellowship

- **Robert and Winifred Curry**
  - Robert and Winifred Curry
  - Founders Circle Fellowship

- **Dennis and Linda Fenton**
  - Dennis and Linda Fenton
  - Founders Circle Fellowship

- **Fletcher Jones Foundation**
  - Fletcher Jones Endowed Fellowship Fund

- **H. Victor Hansen**
  - Hansen Endowed Fellowship Fund

- **Thomas Lee**
  - Thomas H. Lee
  - Founders Circle Fellowship

- **Arthur D. Riggs**
  - Riggs City of Hope Fellowship

- **Hank and Gayle Riggs**
  - Riggs/Carson Endowed Fellowship Fund

- **Rose Hills Foundation**
  - Rose Hills Foundation Science and Engineering Fellowship

- **Sidney J. Weinberg Jr. Foundation**
  - Sidney J. Weinberg Jr. Foundation
  - Endowed Fellowship Matching Challenge

---

Alumni Board

Comprised of KGI graduate volunteers, the Alumni Board meets three times a year to discuss matters of importance to the alumni community, while working to increase networking opportunities for alumni, help develop KGI’s curriculum and assist with student recruitment.

- **Padma Arunachalam (MBS ’05)**
  - Consultant & Chief
  - Pioneer Hybrid

- **Matt Grunseth (MBS ’08)**
  - Manager of Technology Licensing
  - City of Hope

- **Hutch Humphreys (MBS ’03)**
  - Associate Director, Regulatory Affairs
  - Therapeutics, Inc.

- **Aanchal Kamra (MBS ’09)**
  - Program Coordinator, Prostate Cancer Program
  - City of Hope

- **Madhu Lal (MBS ’04)**
  - Postdoctoral Fellow
  - National Institute on Aging

- **Darren Leva (MBS ’05)**
  - Manager, Business Development
  - Althea Technology

- **Ryan Peeler (MBS ’07)**
  - Project Manager
  - Lnx Research

- **Ravneesh Sachdev (MBS ’06)**
  - Senior Manager, Corporate Development
  - Onyx Pharmaceuticals

- **Garry Seid (MBS ’03)**
  - Project Manager
  - Amgen, Inc.

- **Louis Shamel (MBS ’09)**
  - M&A Associate
  - Life Technologies

- **Nicole Sindy (MBS ’09)**
  - Clinical Research Associate
  - Veracyte, Inc.

- **Thomas Storey (MBS ’03)**
  - Manager, Business Development
  - Amgen, Inc.

*Board President*
## Financial Statements

### Statements of Financial Position

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2011</th>
<th>June 30, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$26,947</td>
<td>$139,770</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>$449,166</td>
<td>$514,745</td>
</tr>
<tr>
<td>Prepaid expenses and deposits</td>
<td>$821,460</td>
<td>$388,796</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>$3,238,484</td>
<td>$5,623,383</td>
</tr>
<tr>
<td>Funds held in trust for others</td>
<td>$134,182</td>
<td>$126,682</td>
</tr>
<tr>
<td>Investments</td>
<td>$45,433,492</td>
<td>$40,225,682</td>
</tr>
<tr>
<td>Building investment, net</td>
<td>$5,163,094</td>
<td>$5,358,604</td>
</tr>
<tr>
<td>Buildings and equipment, net</td>
<td>$12,093,890</td>
<td>$12,403,428</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$67,360,715</td>
<td>$64,781,090</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$1,489,182</td>
<td>$1,319,719</td>
</tr>
<tr>
<td>Deposits and deferred revenues</td>
<td>$120,709</td>
<td>$124,390</td>
</tr>
<tr>
<td>Bonds payable and capital lease obligations</td>
<td>$8,791,180</td>
<td>$9,124,000</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>$10,401,071</td>
<td>$10,568,109</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>$19,728,027</td>
<td>$19,571,479</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>$7,918,826</td>
<td>$5,850,054</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>$29,312,791</td>
<td>$28,791,448</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>$56,959,644</td>
<td>$54,212,981</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>$67,360,715</td>
<td>$64,781,090</td>
</tr>
</tbody>
</table>

### Statements of Activities

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2011</th>
<th>June 30, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuition and fees (net of tuition discount)</td>
<td>$2,481,295</td>
<td>$2,011,300</td>
</tr>
<tr>
<td>Private gifts and grants</td>
<td>$1,483,083</td>
<td>$3,821,383</td>
</tr>
<tr>
<td>Private contracts</td>
<td>$185,547</td>
<td>$365,976</td>
</tr>
<tr>
<td>Federal grants and contracts</td>
<td>$1,743,677</td>
<td>$1,639,057</td>
</tr>
<tr>
<td>Investment income</td>
<td>$2,225,945</td>
<td>$1,995,296</td>
</tr>
<tr>
<td>Other revenues</td>
<td>$853,059</td>
<td>$769,980</td>
</tr>
<tr>
<td><strong>Total revenues</strong></td>
<td>$8,972,606</td>
<td>$10,602,992</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Instruction</td>
<td>$3,480,362</td>
<td>$3,435,217</td>
</tr>
<tr>
<td>Research</td>
<td>$2,604,096</td>
<td>$2,903,457</td>
</tr>
<tr>
<td>Academic support</td>
<td>$1,883,743</td>
<td>$1,655,897</td>
</tr>
<tr>
<td>Student services</td>
<td>$1,306,736</td>
<td>$1,377,337</td>
</tr>
<tr>
<td>Institutional support</td>
<td>$4,410,886</td>
<td>$4,084,735</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>$13,885,823</td>
<td>$13,456,643</td>
</tr>
<tr>
<td><strong>Deficiencies of revenues over expenses</strong></td>
<td>$(4,913,217)</td>
<td>$(2,853,651)</td>
</tr>
<tr>
<td><strong>Other Changes in Net Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actuarial adjustment</td>
<td>$(1,139)</td>
<td>$5,479</td>
</tr>
<tr>
<td>Adjustments to contributions receivable</td>
<td>$0</td>
<td>$(10,000)</td>
</tr>
<tr>
<td>Realized and unrealized investment gains, net</td>
<td>$7,678,933</td>
<td>$2,711,700</td>
</tr>
<tr>
<td>Loss on disposal of equipment</td>
<td>$(17,914)</td>
<td>$(35,578)</td>
</tr>
<tr>
<td><strong>Total other changes in net assets</strong></td>
<td>$7,659,880</td>
<td>$2,671,601</td>
</tr>
<tr>
<td><strong>Net Assets - Beginning of Year</strong></td>
<td>$54,212,981</td>
<td>$54,395,031</td>
</tr>
<tr>
<td><strong>Net Assets - End of Year</strong></td>
<td>$56,959,644</td>
<td>$54,212,981</td>
</tr>
</tbody>
</table>